By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


SEARCH JOBS



Key Statistics


Email: info@adamaspharma.com
Ownership: Public

Web Site: Adamas Pharma
Employees:
Symbol: ADMS
 



Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Adamas Pharma (ADMS) Reports Third Quarter 2016 Financial Results 11/4/2016 10:51:59 AM
Adamas Pharma (ADMS) Reports Third Quarter 2016 Financial Results 11/4/2016 10:31:20 AM
Adamas Pharma (ADMS) Submits New Drug Application To U.S. FDA For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Patients With Parkinson’s Disease 10/27/2016 7:34:07 AM
Adamas Pharma (ADMS) Appoints Michael F. Bigham To Board Of Directors 9/23/2016 8:01:33 AM
Allergan (AGN) And Adamas Pharma (ADMS) Announce U.S. Availability Of New Dosage Strengths For NAMZARIC (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease 9/22/2016 8:31:03 AM
Adamas Pharma (ADMS) Announces Results Of EASE LID 3, A Pivotal Trial Of ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson’s Disease Patients At The 4th World Parkinson Congress 9/21/2016 10:48:14 AM
Adamas Pharma (ADMS) Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) At The 4th World Parkinson Congress 9/13/2016 10:01:50 AM
Adamas Pharma (ADMS) Announces New Employment Inducement Grant 9/12/2016 7:51:35 AM
Allergan (AGN) And Adamas Pharmaceuticals (ADMS) Announce Settlement With Amneal Related To NAMZARIC Patent Litigation 8/31/2016 8:40:10 AM
Allergan (AGN) And Adamas Pharmaceuticals (ADMS) Announce New Expanded Indication For NAMZARIC (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease 7/19/2016 6:27:57 AM
1234567
//-->